Jingxun H. Wu

Xiamen, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Journal: JAMA

Published: August 10, 2026

Dietary inflammatory index and lung cancer risk: multi-cohort evidence and plasma proteomic profiles.

Dietary inflammatory index and lung cancer risk: multi-cohort evidence and plasma proteomic profiles.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 18, 2026

Expert consensus on the detection and clinical application of tumor mutational burden.

Expert consensus on the detection and clinical application of tumor mutational burden.

Journal: Cancer biology & medicine

Published: February 18, 2026

An improved fluorescent indicator for monitoring intracellular redox potential.

An improved fluorescent indicator for monitoring intracellular redox potential.

Journal: Redox biology

Published: February 06, 2026

ABTB1 modulates EGFR signaling and confers icotinib sensitivity in lung adenocarcinoma.

ABTB1 modulates EGFR signaling and confers icotinib sensitivity in lung adenocarcinoma.

Journal: Respiratory research

Published: December 22, 2025

The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

Journal: Cancer discovery

Published: November 01, 2025

First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307.

First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307.

Journal: Oncology and therapy

Published: October 03, 2025

Deciphering the immunometabolic axis: a mendelian randomization study of a causal cascade network from immune cell phenotypes to metabolites in esophageal cancer.

Deciphering the immunometabolic axis: a mendelian randomization study of a causal cascade network from immune cell phenotypes to metabolites in esophageal cancer.

Journal: Journal of gastrointestinal oncology

Published: September 20, 2025

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

Journal: Signal transduction and targeted therapy

Published: August 25, 2025

Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study.

Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study.

Journal: Therapeutic advances in medical oncology

Published: June 17, 2025

International guidelines on the diagnosis and treatment of NUT carcinoma.

International guidelines on the diagnosis and treatment of NUT carcinoma.

Journal: Innovation (Cambridge (Mass.))

Published: April 11, 2025

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.

Journal: Cancer biology & medicine

Published: April 09, 2025

Showing 1-12 of 55

Last Updated: 09/26/2026